Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial

IMPORTANCE: Preliminary cost-effectiveness analyses of proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) were based on benefits estimated from reductions in low-density lipoprotein cholesterol that occurred in PCSK9i trials with variable results. The recent Further Cardiovascular Outc...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JAMA Cardiol
Main Authors: Arrieta, Alejandro, Hong, Jonathan C., Khera, Rohan, Virani, Salim S., Krumholz, Harlan M., Nasir, Khurram
Formato: Artigo
Idioma:Inglês
Publicado: American Medical Association 2017
Assuntos:
Brief Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5814995/
https://ncbi.nlm.nih.gov/pubmed/29049467
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2017.3655
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares